Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Large Increase in Short Interest

Virax Biolabs Group Limited (NASDAQ:VRAX) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 149,941 shares, an increase of 639.2% from the November 30th total of 20,284 shares. Based on an average daily volume of 27,512,123 shares, the short-interest ratio is currently 0.0 days. Approximately 6.3% of the company’s stock are sold short. Approximately 6.3% of the company’s stock are sold short. Based on an average daily volume of 27,512,123 shares, the short-interest ratio is currently 0.0 days.

Virax Biolabs Group Trading Up 2.3%

Shares of NASDAQ VRAX opened at $0.36 on Thursday. Virax Biolabs Group has a fifty-two week low of $0.35 and a fifty-two week high of $3.20. The stock has a fifty day moving average of $0.49 and a 200-day moving average of $0.67.

Virax Biolabs Group (NASDAQ:VRAX) last issued its quarterly earnings data on Tuesday, December 2nd. The company reported ($0.27) earnings per share (EPS) for the quarter. The company had revenue of $0.00 million during the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Virax Biolabs Group in a research note on Tuesday, October 14th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Virax Biolabs Group currently has an average rating of “Hold” and a consensus price target of $3.00.

Virax Biolabs Group Company Profile

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.